LONDON and OXFORD, England, Aug. 10, 2011 /PRNewswire/ — Enigma
Diagnostics Limited (Enigma) and GlaxoSmithKline (GSK) today
announced that they have signed agreements for the supply and
commercialization on an exclusive basis of the Enigma® ML
system in Europe and other designated key countries, including
India, Brazil and Russia. The agreements include development by
Enigma of an initial range of respiratory tests for use on its
real-time Polymerase Chain Reaction (PCR) technology platform, and
provide GSK the opportunity to generate revenues from further test
developments in infectious diseases and in other therapeutic areas
relevant to its healthcare business.
The Enigma® ML system has the potential to deliver a result
from a raw sample in under 60 minutes in a point of need setting.
The new collaboration significantly extends the scope of the
Influenza partnership announced in July 2009 for the Enigma® ML
system and builds on GSK’s extensive expertise and heritage within
the respiratory therapeutic area and the extended capabilities
offered by the Enigma® ML system.
Under the terms of this agreement, GSK will make an additional
equity investment and upfront payment, R&D-related payments,
and royalties on net sales of resulting products. Additional
payments will be subject to agreed commercialization
milestones.
John McKinley, Chairman and CEO of Enigma, said: “This is a
major collaboration and represents a significant milestone for
Enigma. These agreements for assay development, commercialization
and supply will leverage GSK’s extensive sales and marketing force
with Enigma’s unique Point of Care system which has potential uses
across a number of human diseases. This is a partnership which will
deliver much needed “test and treat” capability to infectious
disease management.”
Eddie Gray, President, Pharmaceuticals Europe of GSK said: “GSK
is committed to improving the lives of patients suffer
‘/>”/>
